Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Acta Oncol. 2019 Oct 12;59(2):164–170. doi: 10.1080/0284186X.2019.1675907

Table 1 -.

Patient, tumor and treatment characteristics:

Variable All Patients CFRT HFRT
N = 6490 (100%) N = 5378 (83%) N = 1112 (17%)
Age (Mean (min, max)) 75 (40, 90) 74 (40, 90) 76 (41, 90)
BED (Mean (min, max)) 77.0 (61.4, 112.0) 77.6 (70.9, 96.0) 74.3 (61.4, 112.0)
Miles from hosp (Mean (min, max)) 18 (0, 2588) 17 (0, 2420) 20 (0, 2588)
Sex (Female vs Male) 2877 (44%) 2369 (44%) 508 (46%)
Race (White vs Other) 5566 (86%) 4618 (86%) 948 (85%)
Insurance (Medicare vs Other) 4934 (76%) 4069 (76%) 865 (78%)
Urban (Pop. >1 million) 2802 (43%) 2277 (42%) 525 (47%)
Facility Location
 1. East Coast 2570 (40%) 2089 (39%) 481 (43%)
 2. Central 3105 (48%) 2631 (49%) 474 (43%)
 3. West Coast 815 (13%) 658 (12%) 157 (14%)
CDCC_TOTAL
 0 3817 (59%) 3178 (59%) 639 (57%)
 1 1709 (26%) 1411 (26%) 298 (27%)
 2 686 (11%) 558 (10%) 128 (12%)
 3 278 (4.3%) 231 (4.3%) 47 (4.2%)
Year of Diagnosis >2009 2828 (44%) 2312 (43%) 516 (46%)
Tumor location (Upper vs Lower) 4098 (63%) 3391 (63%) 707 (64%)
Tumor laterality (Right vs Left) 3825 (59%) 3162 (59%) 663 (60%)
Histology
 1. Squamous 3081 (47%) 2554 (47%) 527 (47%)
 2. Adeno 1754 (27%) 1461 (27%) 293 (26%)
 3. Other 1655 (26%) 1363 (25%) 292 (26%)
Grade
 1. Well/mod 1323 (20%) 1075 (20%) 248 (22%)
 2. Poor 1940 (30%) 1624 (30%) 316 (28%)
 3. Not determined 3227 (50%) 2679 (50%) 548 (49%)
T-stage 3/4 3337 (51%) 2684 (50%) 653 (59%)
N-stage 2/3 5051 (78%) 4248 (79%) 803 (72%)
Median Income <$38K 1532 (24%) 1264 (24%) 268 (24%)
Education (No HSD vs other) 1219 (19%) 1003 (19%) 216 (19%)
Variable All Patients CFRT HFRT

Continuous variables presented as Mean (Minimum, Maximum). Categorical variables presented as n (%).

HFRT = Hypofractionated Radiotherapy, CFRT = Conventional Radiotherapy, BED = Biologic Effective Dose, HSD = High School Diploma, CDCC = Charlson Deyo Comorbidity Index